Niagen Bioscience 향후 성장
Future 기준 점검 4/6
Niagen Bioscience은 연간 수입과 매출이 각각 24.9%와 15.7% 증가할 것으로 예상되고 EPS는 연간 25.9%만큼 증가할 것으로 예상됩니다.
핵심 정보
24.9%
이익 성장률
25.93%
EPS 성장률
| Personal Products 이익 성장 | 33.4% |
| 매출 성장률 | 15.7% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 07 May 2026 |
최근 향후 성장 업데이트
분석 기사 • Nov 07
Niagen Bioscience, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) just released its quarterly report and things are looking bullish. The company...분석 기사 • Aug 08
Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...Recent updates
내러티브 업데이트 • Apr 22
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that point to steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Recent commentary around Niagen Bioscience centers on how updated Q4 models affect the risk and reward trade off, with attention on both the established core business and the injectable opportunity.내러티브 업데이트 • Apr 07
NAGE: Core Strength And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that reflect steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Analysts see the updated price target as largely reflecting model clean up after Q4, rather than a shift in the overall view on the business.내러티브 업데이트 • Mar 23
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14. This reflects updated models after Q4 results that pointed to steady demand in the core business and potential upside from the injectable segment.내러티브 업데이트 • Mar 06
NAGE: Core Demand And Injectables Outlook Will Support Future Upside
Analysts have trimmed their 12 month price target on Niagen Bioscience from $16.04 to $13.60, citing updated models that reflect steady demand in the core business, potential upside in injectables, adjustments to revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to steady demand in the core business as a key support for current valuation, suggesting the updated models still see the existing portfolio as a meaningful earnings driver.Seeking Alpha • Nov 15
Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years
Summary Niagen Bioscience delivered record Q3 revenue, rising 33% year-over-year, driven by strong Tru Niagen demand and accelerating distribution partnerships. Gross margin expanded to 64.5%, while operating income and adjusted EBITDA grew sharply, reflecting improving scale and cost discipline. Cash from operations already exceeded last year’s total, supporting a new $10 million share repurchase program. The FDA’s reversal on NMN introduces meaningful uncertainty for future demand and competitive dynamics in the NAD+ category. Niagen Bioscience remains financially strong, but sustained momentum in a post-NMN market is unproven, warranting a hold rating. Read the full article on Seeking Alpha분석 기사 • Nov 11
We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve
Even though Niagen Bioscience, Inc. ( NASDAQ:NAGE ) posted strong earnings, investors appeared to be underwhelmed. We...분석 기사 • Nov 07
Niagen Bioscience, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) just released its quarterly report and things are looking bullish. The company...분석 기사 • Oct 03
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues
To the annoyance of some shareholders, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares are down a considerable 25% in...새 내러티브 • Aug 25
Wellness Adoption And Academic Trials Will Define Future Opportunity
Key Takeaways Expanding clinical credibility and global partnerships are opening new high-margin markets, broadening channels, and supporting scalable revenue growth with improved margins. Strong e-commerce performance and diversified product pipeline in preventive health provide resilience, reduced risk, and durable long-term earnings visibility.내러티브 업데이트 • Aug 08
Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
Upward revisions to Niagen Bioscience's price target reflect positive clinical trial results confirming both safety and significant efficacy of its NAD+ supplementation, increased market confidence, and ongoing product and sales momentum, resulting in a higher consensus analyst price target rising from $14.90 to $15.84. Analyst Commentary Positive clinical study results published in a peer-reviewed journal demonstrated that Niagen Bioscience’s NAD+ supplementation is safe for patients with Werner syndrome and achieved a ~140% increase in blood NAD+ levels, along with improvements in liver, kidney, and arterial health markers.분석 기사 • Aug 08
Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...분석 기사 • Aug 06
What You Can Learn From Niagen Bioscience, Inc.'s (NASDAQ:NAGE) P/S After Its 28% Share Price Crash
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...분석 기사 • Jun 17
Market Participants Recognise Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Revenues Pushing Shares 29% Higher
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares have continued their recent momentum with a 29% gain in the last month...분석 기사 • May 10
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
A week ago, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) came out with a strong set of first-quarter numbers that could...분석 기사 • Apr 05
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues
The Niagen Bioscience, Inc. ( NASDAQ:NAGE ) share price has softened a substantial 30% over the previous 30 days...분석 기사 • Mar 29
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE)
Key Insights Niagen Bioscience's estimated fair value is US$7.18 based on 2 Stage Free Cash Flow to Equity Niagen...
새 내러티브 • Feb 09
NIAGEN IV Expansion And FDA Approvals Will Unlock Future Opportunities
Expansion in clinics and strategic partnerships support revenue growth through increased e-commerce and pharmaceutical-grade product sales.분석 기사 • Nov 07
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors
ChromaDex Corporation's ( NASDAQ:CDXC ) strong earnings report was rewarded with a positive stock price move. We did...분석 기사 • Nov 05
Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%
Despite an already strong run, ChromaDex Corporation ( NASDAQ:CDXC ) shares have been powering on, with a gain of 70...분석 기사 • Jul 25
ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company
Those holding ChromaDex Corporation ( NASDAQ:CDXC ) shares would be relieved that the share price has rebounded 25% in...분석 기사 • Jun 15
Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable
Key Insights ChromaDex's Annual General Meeting to take place on 20th of June Total pay for CEO Rob Fried includes...분석 기사 • Jun 05
Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump
ChromaDex Corporation ( NASDAQ:CDXC ) shares have retraced a considerable 26% in the last month, reversing a fair...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 203 | N/A | 44 | 45 | 2 |
| 12/31/2027 | 168 | 29 | 32 | 33 | 4 |
| 12/31/2026 | 143 | 22 | 26 | 21 | 5 |
| 3/31/2026 | 130 | 19 | 4 | 4 | N/A |
| 12/31/2025 | 129 | 17 | 13 | 14 | N/A |
| 9/30/2025 | 125 | 20 | 21 | 21 | N/A |
| 6/30/2025 | 116 | 18 | 21 | 21 | N/A |
| 3/31/2025 | 108 | 14 | 20 | 20 | N/A |
| 12/31/2024 | 100 | 9 | 12 | 12 | N/A |
| 9/30/2024 | 92 | 1 | 4 | 4 | N/A |
| 6/30/2024 | 86 | -1 | 1 | 1 | N/A |
| 3/31/2024 | 83 | -4 | 5 | 5 | N/A |
| 12/31/2023 | 84 | -5 | 7 | 7 | N/A |
| 9/30/2023 | 83 | -6 | 6 | 6 | N/A |
| 6/30/2023 | 81 | -6 | 2 | 2 | N/A |
| 3/31/2023 | 77 | -11 | -6 | -5 | N/A |
| 12/31/2022 | 72 | -17 | -15 | -15 | N/A |
| 9/30/2022 | 69 | -20 | -20 | -20 | N/A |
| 6/30/2022 | 69 | -28 | -22 | -22 | N/A |
| 3/31/2022 | 70 | -27 | -26 | -26 | N/A |
| 12/31/2021 | 67 | -27 | -25 | -24 | N/A |
| 9/30/2021 | 65 | -28 | -20 | -19 | N/A |
| 6/30/2021 | 62 | -23 | -17 | -17 | N/A |
| 3/31/2021 | 60 | -21 | -11 | -11 | N/A |
| 12/31/2020 | 59 | -20 | -11 | -11 | N/A |
| 9/30/2020 | 57 | -23 | -12 | -11 | N/A |
| 6/30/2020 | 55 | -26 | -16 | -15 | N/A |
| 3/31/2020 | 51 | -30 | -23 | -23 | N/A |
| 12/31/2019 | 46 | -32 | N/A | -20 | N/A |
| 9/30/2019 | 42 | -32 | N/A | -25 | N/A |
| 6/30/2019 | 38 | -33 | N/A | -22 | N/A |
| 3/31/2019 | 35 | -33 | N/A | -20 | N/A |
| 12/31/2018 | 32 | -33 | N/A | -21 | N/A |
| 9/30/2018 | 30 | -34 | N/A | -20 | N/A |
| 6/30/2018 | 28 | -29 | N/A | -15 | N/A |
| 3/31/2018 | 24 | -23 | N/A | -14 | N/A |
| 12/30/2017 | 21 | -17 | N/A | -10 | N/A |
| 9/30/2017 | 18 | -10 | N/A | -6 | N/A |
| 7/1/2017 | 16 | -8 | N/A | -6 | N/A |
| 4/1/2017 | 18 | -6 | N/A | 0 | N/A |
| 12/31/2016 | 22 | -4 | N/A | -3 | N/A |
| 10/1/2016 | 22 | -3 | N/A | -4 | N/A |
| 7/2/2016 | 24 | -2 | N/A | -5 | N/A |
| 4/2/2016 | 24 | -1 | N/A | -4 | N/A |
| 1/2/2016 | 18 | -3 | N/A | -2 | N/A |
| 10/3/2015 | 22 | -3 | N/A | -2 | N/A |
| 7/4/2015 | 20 | -3 | N/A | -1 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: NAGE 의 연간 예상 수익 증가율(24.9%)이 saving rate(3.5%)보다 높습니다.
수익 vs 시장: NAGE 의 연간 수익(24.9%)이 US 시장(16.4%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 수익: NAGE 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.
수익 대 시장: NAGE 의 수익(연간 15.7%)이 US 시장(연간 11.4%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: NAGE 의 수익(연간 15.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: NAGE의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/07 19:46 |
| 종가 | 2026/05/07 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Niagen Bioscience, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Susan Anderson | Canaccord Genuity |
| Jeffrey Mark | Farmhouse Equity Research |